Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracey A Day

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current HIV Research|September 17, 2013
Lessons learned from HIV vaccine clinical efficacy trialsTracey A Day, James G Kublin
Clinical Investigation|December 18, 2012
HIV Vaccine Trials Network: activities and achievements of the first decade and beyondJames G Kublin, Cecilia A Morgan, Tracey A Day, et al.
NPJ Vaccines|June 14, 2024
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTICarlos A Fierro, Michal Sarnecki, Bart Spiessens, et al.
Infection and Immunity|October 8, 2014
Mycobacterium tuberculosis strains lacking surface lipid phthiocerol dimycocerosate are susceptible to killing by an early innate host responseTracey A Day, John E Mittler, Molly R Nixon, et al.
European Journal of Immunology|February 22, 2011
Impact of inducible co-stimulatory molecule (ICOS) on T-cell responses and protection against Mycobacterium tuberculosis infectionGeraldine Nouailles, Tracey A Day, Stefanie Kuhlmann, et al.
Microbiology and Molecular Biology Reviews : MMBR|November 28, 2014
Tuberculosis vaccines and prevention of infectionThomas R Hawn, Tracey A Day, Thomas J Scriba, et al.
Vaccines|February 26, 2026
Immunogenicity and Safety of the ExPEC9V <i>Escherichia coli</i> Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 StudyIsabel Leroux-Roels, Tracey A Day, Sofie Deleu, et al.
European Journal of Immunology|March 12, 2010
Secondary lymphoid organs are dispensable for the development of T-cell-mediated immunity during tuberculosisTracey A Day, Markus Koch, Geraldine Nouailles, et al.
Clinical & Translational Immunology|December 20, 2016
A structure-function approach to optimizing TLR4 ligands for human vaccinesDarrick Carter, Christopher B Fox, Tracey A Day, et al.
NPJ Vaccines|September 14, 2018
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trialRhea N Coler, Tracey A Day, Ruth Ellis, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current HIV Research|September 17, 2013
Lessons learned from HIV vaccine clinical efficacy trialsTracey A Day, James G Kublin
Clinical Investigation|December 18, 2012
HIV Vaccine Trials Network: activities and achievements of the first decade and beyondJames G Kublin, Cecilia A Morgan, Tracey A Day, et al.
NPJ Vaccines|June 14, 2024
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTICarlos A Fierro, Michal Sarnecki, Bart Spiessens, et al.
Infection and Immunity|October 8, 2014
Mycobacterium tuberculosis strains lacking surface lipid phthiocerol dimycocerosate are susceptible to killing by an early innate host responseTracey A Day, John E Mittler, Molly R Nixon, et al.
European Journal of Immunology|February 22, 2011
Impact of inducible co-stimulatory molecule (ICOS) on T-cell responses and protection against Mycobacterium tuberculosis infectionGeraldine Nouailles, Tracey A Day, Stefanie Kuhlmann, et al.
Microbiology and Molecular Biology Reviews : MMBR|November 28, 2014
Tuberculosis vaccines and prevention of infectionThomas R Hawn, Tracey A Day, Thomas J Scriba, et al.
Vaccines|February 26, 2026
Immunogenicity and Safety of the ExPEC9V <i>Escherichia coli</i> Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 StudyIsabel Leroux-Roels, Tracey A Day, Sofie Deleu, et al.
European Journal of Immunology|March 12, 2010
Secondary lymphoid organs are dispensable for the development of T-cell-mediated immunity during tuberculosisTracey A Day, Markus Koch, Geraldine Nouailles, et al.
Clinical & Translational Immunology|December 20, 2016
A structure-function approach to optimizing TLR4 ligands for human vaccinesDarrick Carter, Christopher B Fox, Tracey A Day, et al.
NPJ Vaccines|September 14, 2018
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trialRhea N Coler, Tracey A Day, Ruth Ellis, et al.
Pageof 2